Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Serina Therapeutics filed an 8-K on 12/10/25. Routine update.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on December 10, 2025, reporting other events and financial statements. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is incorporated in Delaware and headquartered in Huntsville, Alabama.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report for other events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- December 10, 2025 (date) — Date of report
- Huntsville, Alabama (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits'.
When was Serina Therapeutics, Inc. formerly known as AgeX Therapeutics, Inc.?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc. until June 6, 2017.
Where are Serina Therapeutics, Inc.'s principal executive offices located?
Serina Therapeutics, Inc.'s principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What is the SEC file number for Serina Therapeutics, Inc.?
The SEC file number for Serina Therapeutics, Inc. is 001-38519.
What is the fiscal year end for Serina Therapeutics, Inc.?
The fiscal year end for Serina Therapeutics, Inc. is December 31.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-12-10 16:17:35
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SER NYSE American Indicate
Filing Documents
- ser-20251210xserinatofdare.htm (8-K) — 20KB
- ex991-serinaresponsetofdad.htm (EX-99.1) — 15KB
- 0001708599-25-000138.txt ( ) — 37KB
01 Other Items
Item 8.01 Other Items On December 10, 2025, Serina Therapeutics, Inc. (the "Company") issued a press release providing a regulatory update on the Company's lead SER-252 program for advanced Parkinson's disease, announcing the submission of the Company's complete response to the FDA's clinical hold letter for SER-252, dated November 25, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release, dated December 10 , 2025, on Regulatory Update on SER-252 Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date December 10, 2025 By s Steve Ledger Chief Executive Officer